These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 6819493)

  • 21. Dimethylaminoethanol (deanol): effect on apomorphine-induced stereotypy and an animal model of tardive dyskinesia.
    Davis KL; Hollister LE; Vento AL; Beilstein BA; Rosekind GR
    Psychopharmacology (Berl); 1979 May; 63(2):143-6. PubMed ID: 112632
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Electrophysiological and behavioral assessments of dopamine autoreceptor activation to apomorphine in rats.
    Okuyama S; Shimamura H; Hashimoto S; Aihara H
    Arch Int Pharmacodyn Ther; 1986 Dec; 284(2):246-54. PubMed ID: 3827410
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of cholinergic agonists on apomorphine-induced stereotyped behavior in the rat.
    Sahakian BJ; Growdon JH; Millington WR; Barr JK; Wurtman RJ
    Commun Psychopharmacol; 1978; 2(3):255-62. PubMed ID: 568059
    [No Abstract]   [Full Text] [Related]  

  • 24. Similar effect of estradiol and haloperidol on experimental tardive dyskinesia in monkeys.
    Bédard PJ; Boucher R; Daigle M; Di Paolo T
    Psychoneuroendocrinology; 1984; 9(4):375-9. PubMed ID: 6514933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modification of apomorphine-, physostigmine- and pilocarpine-induced yawning after long-term treatment with neuroleptic or cholinergic agents.
    Ushijima I; Noda Y; Mizuki Y; Yamada M
    Arch Int Pharmacodyn Ther; 1984 Oct; 271(2):180-8. PubMed ID: 6150689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Behavioral evidence for dopamine receptor subsensitivity following chronic haloperidol.
    Lynch MR
    Neuropsychobiology; 1990-1991; 24(2):102-8. PubMed ID: 2151972
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Scopolamine modulates apomorphine-induced behavior in rats treated with haloperidol or SCH 23390.
    Butkerait P; Friedman E
    Eur J Pharmacol; 1988 Mar; 148(2):269-72. PubMed ID: 2897925
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amantadine reduces haloperidol-induced dopamine receptor hypersensitivity in the striatum.
    Allen RM; Lane JD; Brauchi JT
    Eur J Pharmacol; 1980 Jul; 65(2-3):313-5. PubMed ID: 7190503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chronic administration of desipramine or nialamide decreases wet-dog shakes in rats produced by the TRH-analog MK-771.
    Sills MA; Jacobowitz DM
    Brain Res; 1987 Jan; 401(1):195-9. PubMed ID: 3101979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phenytoin potentiation of neuroleptic-induced dyskinesias.
    Sethi KD; Hitri A; Diamond BI
    Mov Disord; 1990; 5(4):325-7. PubMed ID: 2147979
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuroleptic treatment for a substantial proportion of adult life: behavioural sequelae of 9 months haloperidol administration.
    Waddington JL; Gamble SJ
    Eur J Pharmacol; 1980 Oct; 67(4):363-9. PubMed ID: 7192633
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of dopamine agonists in tardive dyskinesia.
    Smith RC; Tamminga CA; Haraszti J; Pandey GN; Davis JM
    Am J Psychiatry; 1977 Jul; 134(7):763-8. PubMed ID: 869053
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thyrotropin-releasing hormone and its analog MK-771 increase the cerebroventricular perfusate content of dihydroxyphenylacetic acid.
    Nielsen JA; Moore KE
    J Neurochem; 1984 Aug; 43(2):593-6. PubMed ID: 6429282
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of dopamine receptor agonists on gastric acid secretion induced by intraventricular administration of thyrotropin-releasing hormone in the perfused stomach of anaesthetized rats.
    Maeda-Hagiwara M; Watanabe K
    Br J Pharmacol; 1983 May; 79(1):297-303. PubMed ID: 6135480
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Animal models of tardive dyskinesia: their use in the search for new treatment methods.
    Goetz CG; Klawans HL; Carvey P
    Mod Probl Pharmacopsychiatry; 1983; 21():5-20. PubMed ID: 6140633
    [No Abstract]   [Full Text] [Related]  

  • 36. Effects of the potential neuroleptic peptide des-tyrosine-gamma-endorphin and haloperidol on apomorphine-induced behavioural syndromes in rats and mice.
    Nickolson VJ; Berendsen HH
    Life Sci; 1980 Oct; 27(15):1377-85. PubMed ID: 7192353
    [No Abstract]   [Full Text] [Related]  

  • 37. Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment.
    Waddington JL; Cross AJ; Gamble SJ; Bourne RC
    Science; 1983 Apr; 220(4596):530-2. PubMed ID: 6132447
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Naloxone prevents and blocks the emergence of neuroleptic-mediated oral stereotypic behaviors.
    Pollock J; Kornetsky C
    Neuropsychopharmacology; 1991 Jun; 4(4):245-9. PubMed ID: 1678260
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Central dopaminergic actions of YM-14673, a new TRH analogue, in rodents.
    Yamamoto M; Ozawa Y; Sasamata M; Koshikawa N; Kobayashi M
    Eur J Pharmacol; 1990 May; 180(2-3):319-24. PubMed ID: 1973117
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of scopolamine pretreatment on stereotyped behavior induced by apomorphine in rats withdrawn from long-term haloperidol administration.
    De-Souza H; Palermo-Neto J
    Braz J Med Biol Res; 1981 Oct; 14(4-5):281-4. PubMed ID: 7201335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.